Overview

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

This protocol will seek to enroll adult otherwise healthy subjects presenting with influenza-like illness (ILI). Subjects will enter the study based on listed inclusion/exclusion criteria, including a positive diagnostic test for influenza virus (IFV).

Phase:

Phase 2

Details

Lead Sponsor:

Ansun Biopharma, Inc.

Collaborator:

National Institutes of Health (NIH)